James M. Frates - Jan 6, 2022 Form 4/A - Amendment Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Financial Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact for James Frates
Stock symbol
AMLX
Transactions as of
Jan 6, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
4/26/2023, 07:34 PM
Date Of Original Report
Jan 10, 2022
Previous filing
Jun 17, 2021
Next filing
Mar 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Conversion of derivative security $0 +19.5K $0.00 19.5K Jan 6, 2022 By Trust F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Series C-1 Preferred Stock Conversion of derivative security $0 -19.5K -100% $0.00* 0 Jan 6, 2022 Common Stock 19.5K By Trust F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date.
F2 This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4.
F3 Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.